^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Omics Core

Company:
NantHealth
Type:
FDA Approved

Details

Evidence
The Omics Core Assay is a qualitative in vitro diagnostic test that uses targeted next generation sequencing of formalin-fixed paraffin-embedded tumor tissue matched with normal specimens from patients with solid malignant neoplasms to detect tumor gene alterations in a broad multi gene panel. The test is intended to provide information on somatic mutations (point mutations and small insertions and deletions) and tumor mutational burden (TMB) for use by qualified health care professionals in accordance with professional guidelines, and is not conclusive or prescriptive for labeled use of any specific therapeutic product. The Omics Core assay targets whole exome sequencing platform to report both overall tumor mutation burden in tumor specimens from 19,396 protein-coding genes (whole exome) and somatic alterations (point mutations, small insertions and deletions) in 468 cancer-relevant genes.
Cancer:
Solid Tumor
Gene:
BCOR (BCL6 Corepressor), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog)
See More ...
Method:
Next-Generation Sequencing (NGS)
Approvals
Date
Cancer
Gene
Drug
By
11/09/19
FDA